Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00601172 · ClinicalTrials.gov registry record · Phase 3
A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.
A Phase 3 study of Nausea and Vomiting, Chemotherapy-Induced, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 710
- Enrollment target
- 20
- Study locations
NCT00601172 is a Phase 3 study of Nausea and Vomiting, Chemotherapy-Induced that has completed, run by GlaxoSmithKline. The registered enrollment target is 710 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT00601172, a Phase 3 study of Nausea and Vomiting, Chemotherapy-Induced, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 710 participants
- Enrollment target
- 20
- Study locations
Study Summary
This a Phase III trial designed to determine if IV casopitant plus dexamethasone and ondansetron is more effective in the prevention of vomiting and nausea then dexamethasone and ondansetrone alone following the administration of moderately emetogenic oxaliplatin-based chemotherapy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dexamethasone
- DRUG Ondansetron
- DRUG Casopitant
Study Locations (20)
California
- GSK Investigational Site - Corona
- GSK Investigational Site - Fountain Valley
- GSK Investigational Site - Riverside
South Carolina
- GSK Investigational Site - Hilton Head Island
- GSK Investigational Site - Mt. Pleasant
- GSK Investigational Site - Sumter
Florida
- GSK Investigational Site - St. Petersburg
- GSK Investigational Site - Tampa
Louisiana
- GSK Investigational Site - Alexandria
- GSK Investigational Site - Baton Rouge
Massachusetts
- GSK Investigational Site - Boston
- GSK Investigational Site - Worcester
Texas
- GSK Investigational Site - Corpus Christi
- GSK Investigational Site - Corpus Christi
Arkansas
- GSK Investigational Site - Hot Springs
Maryland
- GSK Investigational Site - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 710 participants |
| Start Date | 2008-03-10 |
| Est. Completion | 2009-04-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00601172
The ClinicalTrials.gov registry entry for NCT00601172 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 710 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nausea and Vomiting, Chemotherapy-Induced appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT00601172 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, South Carolina, Florida.
Frequently Asked Questions
What is clinical trial NCT00601172 about?
NCT00601172 is a clinical study titled "A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.". This a Phase III trial designed to determine if IV casopitant plus dexamethasone and ondansetron is more effective in the prevention of vomiting and nausea then dexamethasone and ondansetrone alone following the administration of moderately emetogenic oxaliplatin-based chemotherapy.
What is the current status of trial NCT00601172?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 710 participants. The study started on 2008-03-10. Estimated completion is 2009-04-13.
What conditions does trial NCT00601172 study?
This clinical trial studies the following conditions: Nausea and Vomiting, Chemotherapy-Induced.
What interventions are being tested in trial NCT00601172?
The interventions under investigation include: Placebo (DRUG), Dexamethasone (DRUG), Ondansetron (DRUG), Casopitant (DRUG).
Who is sponsoring clinical trial NCT00601172?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00601172 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.